Development of an imaging-based method for fibrosis localization and quantification in the heart with atrial fibrillation.
Development of superparamagnetic MRI contrast agents using a core/shell design, with enhanced biocompatibility and low toxicity.
Identification of possible causes of persistent atrial fibrillation using correlation analysis of the imaging-derived parameters with patient clinical data.
Performing functional MRI on the affected heart segments to identify functional effects of the structural changes.
Activities for the acquisition and protection of industrial property rights.
Information and publicity activities.